A new study in BMC Pregnancy and Childbirth finds that objective information about risk of preeclampsia could be key to driving patient behavior change and creates motivation among pregnant patients to follow provider recommendations on prevention, even among those who are medication-hesitant.
Risk Adjusted Net Present Value: What is the current valuation of Otsuka’s Zipalertinib
The revenue for Zipalertinib is expected to reach an annual total of $47 mn by 2037 in the US based off GlobalData’s Expiry Model. The
December 15, 2024